High-Dose Therapy Improves Progression-Free Survival and Survival in Relapsed Follicular Non-Hodgkin’s Lymphoma: Results From the Randomized European CUP Trial

Abstract

HDT significantly improves PFS and OS. There is no clear evidence of benefit through purging.

Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma

“…Here, 5-year PFS was 59%, which is comparable or superior to results reported by other centers. 3,8,[14][15][16] However, as our trial is a relatively small phase II study, comparisons with other reports should be interpreted with caution.…”

“…Assuming that 4-year PFS among patients with relapsed FL was approximately 50% after auto-SCT alone, 16 our sample size of 23 patients allowed us to detect a greater than or equal to 28% improvement in 4-year PFS with 80% power and 95% confidence. Secondary outcomes were OS, regimen-related toxicity (including infections) and MRD in the PB, BM and stem cell graft.…”

“…[2][3][4][5][6][7][8][9][10][11][12][13][14][15] A recent randomized comparison of auto-SCT versus salvage chemotherapy for relapsed FL showed high response rates, acceptable toxicities and improved PFS and overall survival (OS). 16 Unfortunately, cure has still not been shown with either antibody-based treatment or auto-SCT.…”

Preferences of patients and physicians concerning treatment options for relapsed follicular lymphoma: a discrete choice experiment

“…Auto-SCT confers a significant PFS benefit over conventional CT, however, B50% of patients will relapse within 5 years. 13,14 Allo-SCT is generally accepted to have curative potential for follicular lymphoma and is associated with a markedly reduced relapse rates (B20%), but at the expense of higher treatment-related mortality (B30%), thus resulting in similar OS rates when compared to auto-SCT. 15 Choice between treatment options requires consideration of the goals of therapy (palliative vs prolongation of survival), performance status, previous type of therapy and best response to past therapy.…”

Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I131 tositumomab

“…In 'aggressive' lymphoma, the benefit of such an approach has been demonstrated to be superior to conventional salvage chemotherapy in patients with relapsed disease (Philip et al, 1995) and has an accepted role in those patients whose disease is primary refractory to conventional therapy (Vose et al, 1993;Shipp et al, 1999). In follicular lymphoma, long-term freedom from recurrence may be achieved in those with recurrent disease (Freedman et al, 1999;Apostolidis et al, 2000;Hunault-Berger et al, 2002), and indeed in a randomized study an advantage in both PFS and OS was demonstrated (Schouten et al, 2003). However, many patients do not derive long-term benefit from these procedures coupled with concern about their toxicity has necessitated an urgent need for an improved approach.…”